Brookline Capital Markets Comments on HURA Q1 Earnings

Key Points

• Brookline Capital Markets projects TuHURA will report Q1 2026 EPS of ($0.10) and forecasts FY2026 EPS of ($0.38), improving to ($0.30) by FY2028.
• Analyst coverage is mixed—two Buy ratings and one Sell produce a MarketBeat consensus of "Hold" with a $9.00 average price target, while HC Wainwright maintains a $10 buy and Wall Street Zen recently downgraded to Sell.
• Shares opened at $2.87 (up ~26.4%) with a market cap around $182M, but the company last reported a Q1 EPS loss of ($0.13) that missed estimates, and institutional ownership remains very low (~0.62%).

TuHURA Biosciences, Inc. (NASDAQ:HURA - Free Report) - Equities researchers at Brookline Capital Markets issued their Q1 2026 earnings per share estimates for TuHURA Biosciences in a research note issued on Thursday, April 9th. Brookline Capital Markets analyst K. Raja forecasts that the company will post earnings of ($0.10) per share for the quarter. Brookline Capital Markets also issued estimates for TuHURA Biosciences' Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.38) EPS, FY2027 earnings at ($0.36) EPS and FY2028 earnings at ($0.30) EPS.

Other research analysts have also issued reports about the company. Wall Street Zen lowered TuHURA Biosciences from a "hold" rating to a "sell" rating in a research report on Tuesday, April 7th. Weiss Ratings reissued a "sell (e+)" rating on shares of TuHURA Biosciences in a research report on Thursday, January 22nd. Finally, HC Wainwright reissued a "buy" rating and set a $10.00 price target on shares of TuHURA Biosciences in a research report on Tuesday, February 3rd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, TuHURA Biosciences has an average rating of "Hold" and a consensus price target of $9.00.

TuHURA Biosciences Stock Up 26.4%

Shares of TuHURA Biosciences stock opened at $2.87 on Tuesday. The firm has a market capitalization of $182.47 million, a PE ratio of -4.56 and a beta of -0.32. TuHURA Biosciences has a 12-month low of $0.41 and a 12-month high of $4.44. The stock's fifty day moving average is $1.56 and its 200-day moving average is $1.60.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last announced its earnings results on Tuesday, March 31st. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01).

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Bank of America Corp DE acquired a new position in TuHURA Biosciences in the 4th quarter worth about $59,000. Barclays PLC increased its stake in shares of TuHURA Biosciences by 42.6% during the 4th quarter. Barclays PLC now owns 52,615 shares of the company's stock worth $40,000 after purchasing an additional 15,725 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of TuHURA Biosciences during the 2nd quarter worth $31,000. Goldman Sachs Group Inc. acquired a new position in shares of TuHURA Biosciences during the 4th quarter worth $30,000. Finally, Invesco Ltd. acquired a new position in shares of TuHURA Biosciences during the 2nd quarter worth $30,000. 0.62% of the stock is owned by institutional investors and hedge funds.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company's core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA's approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.